Results 41 to 50 of about 51,116 (225)

Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF [PDF]

, 2017
Background: Compared to heart failure patients with higher systolic blood pressure (SBP), those with lower SBP have a worse prognosis. To make matters worse, the latter patients often do not receive treatment with life-saving therapies that might ...
Böhm, Michael, Gong, Jianjian, Jhund, Pardeep, Lefkowitz, Martin P., McMurray, John J.V., Packer, Milton, Rizkala, Adel R., Rouleau, Jean L., Shi, Victor C., Solomon, Scott D., Swedberg, Karl, Young, Robin, Zile, Michael R.   +12 more
core   +1 more source

Type of atrial fibrillation and clinical outcomes in patients with heart failure and reduced ejection fraction [PDF]

, 2017
Background: Atrial fibrillation (AF) is common in heart failure (HF), but the outcome by type of AF is largely unknown. Objectives: This study investigated outcomes related to type of AF (paroxysmal, persistent or permanent, or new onset) in 2 ...
Abraham, William T., Desai, Akshay S., Dickstein, Kenneth, Jhund, Pardeep S., Køber, Lars, McMurray, John J.V., Mogensen, Ulrik M., Packer, Milton, Rouleau, Jean L., Solomon, Scott D., Swedberg, Karl, Zile, Michael R.   +11 more
core   +3 more sources

Trends in 25 years of antihypertensive agent utilization in Croatia – an alert for scientific community and healthcare providers

British Journal of Clinical Pharmacology, EarlyView.
Aims Hypertension is a leading modifiable risk factor for cardiovascular mortality worldwide. This study aimed to evaluate 25‐year trends in antihypertensive agent (AHA) utilization in Croatia between 2000 and 2024. Methods We conducted a national, population‐based analysis using IMS and IQVIA pharmaceutical databases.
Andrej Belančić, Marta Kučan Štiglić, Ana Jelaković, Bojan Jelaković, Dinko Vitezić   +4 more
wiley   +1 more source

Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. [PDF]

, 2016
AimsIn this analysis, we utilized data from PARADIGM-HF to test the hypothesis that participants who exhibited any dose reduction during the trial would have similar benefits from lower doses of sacubitril/valsartan relative to lower doses of enalapril ...
Claggett, Brian, Desai, Akshay S, Lefkowitz, Martin, McMurray, John JV, Packer, Milton, Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Investigators, Rouleau, Jean, Shi, Victor, Solomon, Scott D, Swedberg, Karl, Teerlink, John R, Vardeny, Orly, Zile, Michael R   +12 more
core   +1 more source

Pharmacological effects of raas blockade in ischemic nephropathy [PDF]

, 2016
Background: The management of ischemic nephropathy due to atherosclerotic renal artery stenosis has become increasingly conservative in the modern era, with current guidelines recommending optimized medical therapy as the initial step.
Barbano, Biagio, Cianci, Rosario, Coppolino, Giuseppe, Di Mario, Francesca, Farrah, Tariq E., Fuiano, Giorgio, Gigante, Antonietta, Rivoli, Laura, Rosato, Edoardo   +8 more
core   +1 more source

Sacubitril/valsartan for the treatment of non‐obstructive hypertrophic cardiomyopathy: An open label randomized controlled trial (SILICOFCM)

European Journal of Heart Failure
Sacubitril/valsartan treatment reduces mortality and hospitalizations in heart failure with reduced ejection fraction but has limited application in hypertrophic cardiomyopathy (HCM).
L. Velicki, Dejana Popović, N. Okwose, A. Preveden, M. Tešić, M. Tafelmeier, S. Charman, F. Barlocco, Guy A. MacGowan, P. Seferovic, Nenad Filipović, A. Ristić, I. Olivotto, L. S. Maier, D. Jakovljevic   +14 more
semanticscholar   +1 more source

Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension

ESC Heart Failure, 2022
Prior studies have not fully characterized the haemodynamic effects of the angiotensin receptor‐neprilysin inhibitor (ARNI) sacubitril/valsartan in heart failure with preserved ejection fraction and pulmonary hypertension (HFpEF–PH).
P. Codina, M. Domingo, E. Barcelo, P. Gastelurrutia, D. Casquete, Joan Vila, O. Abdul-Jawad Altisent, G. Spitaleri, G. Cediel, E. Santiago-Vacas, E. Zamora, M. Ruiz-Cueto, J. Santesmases, R. de la Espriella, D. Pascual-Figal, J. Núñez, J. Lupón, A. Bayés‐Genís   +17 more
semanticscholar   +1 more source

The quantitative impact of metabolism‐inhibiting drugs on the occurrence of adverse drug reactions—A backward selection approach

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The quantitative effect of several inhibitory drugs on the development of adverse drug reactions (ADRs) is currently difficult to estimate. Our aim was to identify metabolic pathways, which, when inhibited, increase the risk for certain ADRs, and to use this system to consider comedication at individual level. Methods Data of a prospective
Judith Berres, Justyna Wozniak, Hannah Fölsch, Anja Knueppel‐Ruppert, Verena Graeff, Andrea Kriegisch‐Stumpf, Harald Dormann, Julia C. Stingl, Katja S. Just   +8 more
wiley   +1 more source

What can we learn from SOCRATES: more questions than answers? [PDF]

, 2017
This editorial refers to ‘Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) Study’, by B ...
Cleland, John G.F., Mueller, Christian
core   +1 more source

Sacubitril-Valsartan in Patients Requiring Hemodialysis

JAMA Network Open
Key Points Question Is the use of sacubitril-valsartan associated with reduced risk of all-cause mortality and hospitalization among individuals requiring hemodialysis for heart failure with reduced ejection fraction (HFrEF)? Findings In this comparative
Dustin Le, Morgan E. Grams, Josef Coresh, Jung-Im Shin   +3 more
semanticscholar   +1 more source